
1. malar j. 2019 apr 2;18(1):114. doi: 10.1186/s12936-019-2749-3.

polymorphisms pvkelch12 gene amplification pvplasmepsin4 plasmodium 
vivax thailand, lao pdr cambodia.

duanguppama j(1)(2), mathema vb(1), tripura r(2), day npj(2)(3), maxay m(4)(5),
nguon c(6), von seidlein l(2), dhorda m(2), peto tj(2), nosten f(2)(3)(7), white 
nj(2)(3), dondorp am(2)(3), imwong m(8)(9).

author information: 
(1)department molecular tropical medicine genetics, faculty tropical
medicine, mahidol university, bangkok, thailand.
(2)mahidol-oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand.
(3)centre tropical medicine, churchill hospital, oxford, uk.
(4)lao-oxford-mahosot hospital-wellcome trust research unit, mahosot hospital,
vientiane, lao people's democratic republic.
(5)institute research education development, university health
sciences, vientiane, lao people's democratic republic.
(6)national centre parasitology, entomology & malaria control, ministry of
health, phnom penh, cambodia.
(7)shoklo malaria research unit, mae sot, faculty tropical medicine, mahidol
university, mae sot, thailand.
(8)department molecular tropical medicine genetics, faculty tropical
medicine, mahidol university, bangkok, thailand. noi@tropmedres.ac.
(9)mahidol-oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand. noi@tropmedres.ac.

background: mutations pfkelch13 pfplasmepsin2/3 gene amplification are
well-established markers artemisinin piperaquine resistance plasmodium
falciparum, widespread problem greater mekong subregion (gms). the
plasmodium vivax parasite population experienced varying drug pressure
dependent local drug policies. investigated correlation drug
pressure artemisinins piperaquine mutations p. vivax
orthologous genes pvkelch12 pvplasmepsin4 (pvpm4), candidate resistance
markers.
methods: blood samples 734 p. vivax patients obtained thailand
(n = 399), lao pdr (n = 296) cambodia (n = 39) 2007 2017.
pvkelch12 pvpm4 amplified sequenced assess gene mutations. to
assess pvpm4 gene amplification, taqman® real-time pcr method developed and
validated. selection non-synonymous mutations assessed ratio with
synonymous mutations (ka/ks ratios). mutation rates compared the
estimated local drug pressure.
results: polymorphisms pvkelch12 rare. pvkelch12 mutations v552i, k151q
and m124i observed 1.0% (7/734) p. vivax samples. v552i most
common mutation frequency 0.7% (5/734), (4/5) observed in
ubon ratchathani, thailand. polymorphisms pvpm4 common, a
frequency 40.3% (123/305) 305 samples thailand, lao pdr cambodia, 
but related estimated piperaquine drug pressure these
areas (pearson's χ2 test, p = 0.50). pvpm4 mutation v165i frequent in
tak, thailand (40.2%, 43/107) followed pailin, cambodia (43.5%, 37/85),
champasak, lao pdr (40.4%, 23/57) ubon ratchathani, thailand (35.7%, 20/56). 
pvpm4 amplification observed 141 samples thailand cambodia.
for pvkelch12 pvpm4, areas time points, ka/ks
values were < 1, suggesting purifying selection.
conclusions: novel real-time pcr-based method assess p. vivax pvpm4 gene
amplification developed. drug pressure artemisinins piperaquine in
the gms clearly related signatures selection mutations the
p. vivax orthologous resistance genes pvkelch12 pvpm4 areas under
investigation. current resistance p. vivax drugs unlikely and
additional observations including analysis associated clinical data these
regions could clarify current findings.

doi: 10.1186/s12936-019-2749-3 
pmcid: pmc6444602
pmid: 30940150  [indexed medline]

